Toxicity management in HCC treatment is discussed by medical experts.
The transcript is part of a medical expert discussion on the management of hepatocellular carcinoma (HCC) and its treatment strategies, focusing on the challenges of immunotherapy and the importance of education for both physicians and patients. The experts emphasize the need for vigilance as adverse events can occur unpredictably and stress the significance of recognizing early signs of potential complications, such as headaches and diarrhea. They discuss the importance of comprehensive patient support systems, including access to various specialists like ophthalmologists, rheumatologists, and dermatologists, as well as the role of nurse navigators and the implementation of referral systems to overcome barriers to care. The conversation highlights the complexity of managing treatment toxicities, especially in the context of the COVID era, where distinguishing between different symptoms can be challenging. The experts stress the significance of understanding the patient’s social background and support system, with a particular focus on optimizing care for vulnerable groups like the elderly or those with poor socioeconomic status. They emphasize the necessity of considering the individual patient’s quality of life and maintaining a patient-centered approach throughout the treatment process. The discussion underscores the importance of clinical pathways and the practical application of therapeutic approaches in real-world settings, addressing the gap between clinical trials and actual patient outcomes.
Overall, the conversation reflects the multidimensional nature of managing HCC, with a strong emphasis on patient education, comprehensive support systems, and a holistic understanding of the patient’s social and clinical context. The experts advocate for a personalized and proactive approach to managing treatment toxicities, ensuring optimal patient care and quality of life throughout the treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More
2 Commerce Drive
Cranbury, NJ 08512